Barnett BS
Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Lutheran Hospital, Cleveland Clinic, Cleveland, Ohio.
ArticlePsychedelics
From Schedule I to the Clinic-Insights Into Psychedelic Drug Development From GHB.
ArticlePsychedelics
Psychological Adverse Effects of Psychedelic Use.
PreprintPsilocybin
Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations
ArticlePsilocybin
Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.
ArticleLSD
Who Keeps Using Lysergic Acid Diethylamide? Correlates of Past-Year Use in People Who Initiated Use at least Five Years Ago.
ArticlePsychedelics
Psychiatric Residents' Perspectives on Psychedelics and Psychedelic Assisted Therapy.
ArticleLSD
Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019.
PreprintKetamine
Esketamine implementation challenges in psychiatry: A qualitative analysis of mental healthcare providers’ social media commentary
ArticleLSD
Exploring Gender-Themed Lysergic Acid Diethylamide Experiences: A Subreddit Analysis.
ArticleMDMA
Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities.
ArticlePsilocybin
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
ArticlePsilocybin
Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation.
ArticlePsilocybin
Psychedelic-assisted therapy: An overview for the internist.
ArticlePsilocybin
Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts.
ArticlePsilocybin
Practical considerations in the establishment of psychedelic research programs.
PreprintPsilocybin
A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics
ArticlePsychedelics
New Billing Codes Offer Opportunity to Investigate Psychedelic Treatment.
ArticlePsilocybin
Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine.
ArticleLSD
Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?
ArticlePsilocybin
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.
ArticleKetamine
Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans.
ArticlePsilocybin
Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges.
ArticleKetamine
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.
ArticlePsilocybin
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD.
PreprintLSD
Perceived risk of LSD use in the United States from 2015-2019: Are Americans assessing LSD’s risk profile more favorably?
ArticlePsychedelics
Psychedelic Medicine's Future Depends on Proactive Development of a Robust Medical Billing and Coding Strategy.
PreprintLSD
LSD use in the United States: Examining user demographics and their evolution from 2015-2019
ArticlePsilocybin
Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.
ArticlePsilocybin
Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
PreprintPsilocybin
Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
ArticlePsilocybin
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
ArticlePsilocybin